CD274 and undifferentiated pleomorphic sarcoma: These results are also supported by a recent pooled analysis of anti-PD1 and anti-PD-L1 phase II clinical trials where undifferentiated pleomorphic sarcoma exhibited the highest response rates to treatment [50].